PDCD1 and cancer: Since cancer-specific T-cell responses might be suppressed through PD-1/PD-L1 interactions, blocking this pathway therapeutically has emerged as a promising approach, with early clinical trials showing positive results in cHL, melanoma, and non–small cell lung cancer [9].